Key result
Among patients with HFrEF referred to a community clinic, only 21% fulfilled the PARADIGM-HF randomization criteria, though this proportion rose to 60% if background medication was ignored.
Why the study?
What proportion of real-world patients with HFrEF are eligible for sacubitril-valsartan based on PARADIGM-HF trial criteria?
Observational (n=6,131)
No
What proportion of real-world patients with HFrEF are eligible for sacubitril-valsartan based on PARADIGM-HF trial criteria?
A minority of real-world HFrEF patients meet the strict PARADIGM-HF trial criteria for sacubitril-valsartan, primarily due to lack of symptoms, low NT-proBNP, or sub-target background medical therapy.
No takes yet. Share an insight, caveat, or question.
Real-world HFrEF eligibility for sacubitril-valsartan remains low under strict criteria; leaves open optimal use and effectiveness beyond trial populations.
Pellicori et al. (2017) conducted an observational in Chronic Heart Failure (n=6,131). PARADIGM-HF eligibility criteria was evaluated on Proportion of HFrEF patients fulfilling PARADIGM-HF randomization criteria. Among patients with HFrEF referred to a community clinic, only 21% fulfilled the PARADIGM-HF randomization criteria, though this proportion rose to 60% if background medication was ignored.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: